Aprea Therapeutics, Inc. Stock Analysis & AI Score
Aprea Therapeutics, Inc. (APRE) has an ST Score of 60.6 (B), driven by its Financial Strength (A+) and held back by its Momentum (B-). Analysts rate it Buy.
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Aprea Therapeutics, Inc. (APRE) has an ST Score of 60.6 (B), driven by its Financial Strength (A+) and held back by its Momentum (B-). Analysts rate it Buy.
- Strongest
- Financial StrengthA+
- Weakest
- MomentumB-
All factor grades
- Financial StrengthA+
- ProfitabilityB
- GrowthB
- ValuationB-
- MomentumB-
- Piotroski3/9
Contact
APRE stock: frequently asked questions
What is APRE's ST Score?
Aprea Therapeutics, Inc. (APRE) has an ST Score of 60.6 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is APRE a buy, hold, or sell?
Analysts rate APRE a Buy. Our ST Score grades it B (60.6/100). The ST Score is a data-driven signal, not a recommendation.
What are APRE's factor grades?
Valuation B-, Profitability B, Financial Strength A+, Momentum B-, Growth B.
What is APRE's valuation grade?
Aprea Therapeutics, Inc. (APRE) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is APRE's growth grade?
Aprea Therapeutics, Inc. (APRE) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is APRE's profitability grade?
Aprea Therapeutics, Inc. (APRE) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is APRE's financial strength grade?
Aprea Therapeutics, Inc. (APRE) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is APRE's Piotroski score?
Aprea Therapeutics, Inc. (APRE) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.